Title:
COMBINATION OF DOCETAXEL ALBUMIN COMPOSITION AND IMMUNE CHECKPOINT INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/247846
Kind Code:
A1
Abstract:
Disclosed is the use of a docetaxel albumin composition and an immune checkpoint inhibitor in the treatment of tumors, particularly in the treatment of colon cancer, liver cancer, melanoma and head and neck squamous carcinoma, including the pharmaceutical use, a pharmaceutical composition or a treatment method. When the docetaxel albumin composition is clinically used, corticosteroid pretreatment is not needed, so that the docetaxel albumin composition can be efficiently combined with the immune checkpoint inhibitor to generate a synergistic anti-tumor effect.
Inventors:
LI CHUNLEI (CN)
ZHANG XIAOJUN (CN)
YAO XUEKUN (CN)
HE XIAOLIN (CN)
LI GUIXIA (CN)
QI HUANHUAN (CN)
SHU YUN (CN)
ZHAO YUANYUAN (CN)
CHEN DONGJIAN (CN)
LIU JIAHUI (CN)
ZHANG XIAOJUN (CN)
YAO XUEKUN (CN)
HE XIAOLIN (CN)
LI GUIXIA (CN)
QI HUANHUAN (CN)
SHU YUN (CN)
ZHAO YUANYUAN (CN)
CHEN DONGJIAN (CN)
LIU JIAHUI (CN)
Application Number:
PCT/CN2022/094859
Publication Date:
December 01, 2022
Filing Date:
May 25, 2022
Export Citation:
Assignee:
CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)
International Classes:
A61K45/06; A61K9/14; A61K31/337; A61K39/395; A61P35/00
Foreign References:
| CN105828837A | 2016-08-03 | |||
| US20200061020A1 | 2020-02-27 | |||
| CN101361731A | 2009-02-11 | |||
| CN106137969A | 2016-11-23 |
Other References:
GU ZILI; WANG QINGJIE; SHI YANBIN; HUANG YI; ZHANG JING; ZHANG XINKE; LIN GUIMEI: "Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity", JOURNAL OF CONTROLLED RELEASE, vol. 286, 7 August 2018 (2018-08-07), AMSTERDAM, NL , pages 369 - 380, XP085478008, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2018.08.011
ARRIETA OSCAR, BARRÓN FELICIANO, RAMÍREZ-TIRADO LAURA ALEJANDRA, ZATARAIN-BARRÓN ZYANYA LUCIA, CARDONA ANDRÉS F., DÍAZ-GARCÍA DIEG: "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer : The PROLUNG Phase 2 Randomized Clinical Trial", JAMA ONCOLOGY, vol. 6, no. 6, 9 April 2020 (2020-04-09), US , pages 856 - 864, XP093008559, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2020.0409
MA CHENG-LONG; SHEN DONG: "Clinical Observation of PD-1 Antibody Combined with Docetaxel in the Treatment of Advanced Lung Cancer after First-line Chemotherapy", CHINESE JOURNAL OF MEDICINE, vol. 54, no. 11, 1 November 2019 (2019-11-01), pages 1244 - 1246, XP093008590, ISSN: 1008-1070, DOI: 10.3969/j.issn.1008-1070.2019.11.026
ARRIETA OSCAR, BARRÓN FELICIANO, RAMÍREZ-TIRADO LAURA ALEJANDRA, ZATARAIN-BARRÓN ZYANYA LUCIA, CARDONA ANDRÉS F., DÍAZ-GARCÍA DIEG: "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer : The PROLUNG Phase 2 Randomized Clinical Trial", JAMA ONCOLOGY, vol. 6, no. 6, 9 April 2020 (2020-04-09), US , pages 856 - 864, XP093008559, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2020.0409
MA CHENG-LONG; SHEN DONG: "Clinical Observation of PD-1 Antibody Combined with Docetaxel in the Treatment of Advanced Lung Cancer after First-line Chemotherapy", CHINESE JOURNAL OF MEDICINE, vol. 54, no. 11, 1 November 2019 (2019-11-01), pages 1244 - 1246, XP093008590, ISSN: 1008-1070, DOI: 10.3969/j.issn.1008-1070.2019.11.026
Attorney, Agent or Firm:
INSIGHT INTELLECTUAL PROPERTY LIMITED (CN)
Download PDF: